Viewing Study NCT01232504

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:12 PM
Ignite Modification Date: 2026-02-12 @ 4:19 PM
Study NCT ID: NCT01232504
Status: COMPLETED
Last Update Posted: 2014-11-04
First Post: 2010-10-25
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mycoses View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Allo-HSCT View
None rhGM-CSF View
None Systemic fungal infection (SFI) View